{"id":390655,"date":"2018-06-08T00:00:00","date_gmt":"2018-06-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0013-2018-biopharma-asthma-unmet-need-severe-asthma-us-eu-2018\/"},"modified":"2026-04-18T23:25:19","modified_gmt":"2026-04-18T23:25:19","slug":"unneim0013-2018-biopharma-asthma-unmet-need-severe-asthma-us-eu-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0013-2018-biopharma-asthma-unmet-need-severe-asthma-us-eu-2018\/","title":{"rendered":"Asthma | Unmet Need | Severe Asthma | US\/EU | 2018"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>Despite the availability of multiple anti-inflammatory agents and bronchodilators, considerable unmet need remains for patients with severe asthma. Typical treatments for this disease subpopulation include combination therapy regimens with several inhaled and\/or oral therapies as well as biologics (Roche\/Novartis\u2019s Xolair, GSK\u2019s Nucala, Teva\u2019s Cinqair\/Cinqaero, and\u2014now\u2014AstraZeneca\u2019s Fasenra). Nevertheless, a sizable proportion of severe asthmatics remain inadequately controlled with currently available treatments. With quantitative insight into an assessment of the current level of unmet need in severe asthma by U.S. pulmonologists\u00a0and allergists\u00a0as well as European pulmonologists, we analyze remaining commercial opportunities and discuss how emerging therapies, such as Dupixent (Sanofi\/Regeneron) and tezepelumab (Amgen\/AstraZeneca), may capitalize on these opportunities.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What clinical\/nonclinical attributes are the key influencers of\u00a0physicians\u2019 prescribing decisions for severe asthma? For example, how important is the availability of a biomarker predictive of response to therapy?<\/li>\n<li>How do current asthma biologics and conventional combination therapy regimens perform on the aforementioned\u00a0attributes? For example, which currently available biologic is viewed as the best performer at\u00a0reducing asthma exacerbation rates?<\/li>\n<li>What are the prevailing areas of unmet need and where are the remaining commercial opportunities in severe asthma?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to physicians for a hypothetical new drug for severe asthma?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong>\u00a0United States, United Kingdom, Germany.<\/p>\n<p><strong>Primary research:\u00a0<\/strong>Survey of 33\u00a0U.S. pulmonologists, 27 U.S. allergists, and 30\u00a0European pulmonologists\u00a0fielded in March\u00a02018.<\/p>\n<p><strong>Key companies:<\/strong>\u00a0GlaxoSmithKline, AstraZeneca, Teva, Regeneron, Sanofi, Boehringer Ingelheim, Amgen, Novartis, Roche,\u00a0Chiesi.<\/p>\n<p><strong>Key drugs:<\/strong>\u00a0Advair\/Seretide, Symbicort, Dulera, Foster, Breo\/Relvar, Flutiform, Spiriva, Xolair, Nucala, Cinqair\/Cinqaero, Fasenra, oral prednisone.<\/p>\n","protected":false},"template":"","class_list":["post-390655","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-asthma","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390655\/revisions"}],"predecessor-version":[{"id":393779,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390655\/revisions\/393779"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}